An Evaluation of the Subcutaneous Depot Release of TV-46000, A Novel Long-Acting Injectable (LAI) Formulation of Risperidone, Under Extreme Conditions in Dogs, Minipigs and Humans

An Evaluation of the Subcutaneous Depot Release of TV-46000, A Novel Long-Acting Injectable (LAI) Formulation of Risperidone, Under Extreme Conditions in Dogs, Minipigs and Humans

Background: TV-46000 (Uzedy, Teva), a long-acting subcutaneous antipsychotic, is an injectable formulation of risperidone and is approved by the FDA for the treatment of schizophrenia in adults. Its innovative copolymer-based drug delivery depot technology (licensed from MedinCell, Jacou, France) al...

Full description

Saved in:
Bibliographic Details
Main Authors: Lilach Steiner, David Bibi, Avia Merenlender Wagner, Pavel Farkas, Safra Rudnick-Glick, Pippa Loupe, Hussein Hallak
Format: Article
Language:English
Published: MDPI AG 2025-01-01
Series:Pharmaceutics
Subjects:
risperidone
TV-46000
schizophrenia
long-acting injectable
antipsychotic
drug delivery depot technology
Online Access:https://www.mdpi.com/1999-4923/17/2/150
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://www.mdpi.com/1999-4923/17/2/150

Similar Items